Researchers in Sweden found that people who have the APOE Alzheimer's gene and who live alone in middle age after being widowed or separated from a life partner, are at higher risk of developing dementia. The study is the work of Dr Krister Hakannson, a research fellow at the Karolinska Institute in Stockholm, and colleagues, and is published in the 2 July online issue of the BMJ.
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows: 1.
Scientists at UC Santa Barbara and several other institutions have found laboratory evidence that a cluster of peptides may be the toxic agent in Alzheimer's disease. Scientists say the discovery may lead to new drugs for the disease. In an article published this week in Nature Chemistry, the researchers explain the process in which the toxic Amyloid Beta 42 peptides aggregate, and outline the new technology they use to study these peptides.
A human growth factor that stimulates blood stem cells to proliferate in the bone marrow reverses memory impairment in mice genetically altered to develop Alzheimer's disease, researchers at the University of South Florida and James A. Haley Hospital found.
On June 11, the National Institute for Health and Clinical Excellence (NICE) announced that, following consultation with stakeholders on the economic model that underpinned NICE's 2006 guidance on the use of drugs to treat Alzheimer's disease, the guidance remains unchanged despite recognising significant errors within their model.
Four Alzheimer's caregivers share their stories and tips in this roundtable discussion from ABC News.
Fluctuating hormone levels make women more vulnerable to ADHD, Alzheimer's, and schizophrenia at certain times of life.
An Institute of Medicine (IOM) committee is urging the U.S. government to fund studies to compare treatment options for ADHD, Alzheimer's disease, and other conditions.
Patients who take a cholesterol-lowing statin may be protected against Alzheimer's disease, a new study has found.
- NICE Commit to Reviewing Existing Guidance 'As Soon As Possible'
LONDON, July 1/PRNewswire/ -- On June 11, the National Institute for Health and Clinical Excellence (NICE) announced that, following consultation with stakeholders on the economic... (Source: Drugs.com - Pharma News)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
Older Entries
